Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: Pooled analysis of 1359 patients in four phase 2 trials

European Heart Journal

Volumn 35, Issue 33, 2014, Pages 2249-2259

  Stein, Evan A ^a   Giugliano, Robert P ^b   Koren, Michael J ^c   Raal, Frederick J ^d   Roth, Eli M ^e   Weiss, Robert ^f   Sullivan, David ^g   Wasserman, Scott M ^h   Somaratne, Ransi ^h   Kim, Jae B ^h   Yang, Jingyuan ^h   Liu, Thomas ^h   Albizem, Moetaz ^h   Scott, Rob ^h   Sabatine, Marc S ^b  

^a Metab and Atherosclerosis Res Ctr   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Jacksonville Center for Clinical Research   (United States)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e Sterling Research Group   (United States)

^f Maine Research Asocits   (United States)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h AMGEN INC   (United States)

Author keywords

Low density lipoprotein cholesterol; Proprotein convertase subtilizin kexin type 9; Randomized controlled trials

Indexed keywords

APOLIPOPROTEIN B; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE SUBTILIZIN KEXIN TYPE 9; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN;

AGED; ARTHRALGIA; ARTICLE; BACKACHE; CEREBROVASCULAR DISEASE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYOPATHY; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; DRUG EFFECTS; HYPERLIPIDEMIAS; IMMUNOLOGY; LIPID METABOLISM; META ANALYSIS; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84922670093     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu085     Document Type: Article

References (27)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
2. Task Force for the Management of Dyslipidaemias of the European Society of Cardiology, The European Atherosclerosis Society, Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Perrone Filardi P, Riccardi G, Storey RF,Wood D, E. S. C. Committee for Practice Guidelines, Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217: S1-S44.
3. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
4. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, KoenigW, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, Jupiter Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
5. Canner PL, Berge KG,Wenger NK, Stamler J, Friedman L, Prineas RJ, FriedewaldW. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am Coll Cardiol 1986;8:1245-1255.
6. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
7. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, Jukema JW, Santos RD, Verdejo J, Messig M, McPherson R, Seung KB, Tarasenko L, Lipid Treatment Assessment Project I. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009;120:28-34.
8. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderatemuscular symptoms with high-dosage statin therapy in hyperlipidemic patients - The PRIMO study. Cardiovasc Drugs Ther 2005;19:403-414.
9. Stein EA, Swergold GD. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr Atheroscler Rep 2013;15:310.
10. Dias CS, Shaywitz AJ,Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, Stein EA. Effects of AMG 145 on low-density lpoprotein cholesterol levels: Results from 2 randomized, double-blind, placebo-controlled, ascendingdose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012;60:1888-1898.
11. Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M,Wasserman SM. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/ kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012;380:1995-2006.
12. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebocontrolled, dose-ranging, phase 2 study. Lancet 2012;380:2007-2017.
13. Raal F, Scott R, Somaratne R, Bridges I, Li G,Wasserman SM, Stein EA. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial. Circulation 2012;126:2408-2417.
14. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V,Wasserman SM, Stein EA. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS Randomized Trial. JAMA 2012;308: 2497-2506.
15. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59: 2344-2353.
16. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M,Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366: 1108-1118.
17. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367: 1891-1900.
18. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centres for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. Clin Lab Med 1989;9:105-135.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
20. Hunninghake D, Miller VT, Palmer RH, Schonfeld G, Stein EA et al. (Lovastatin Study Group II). Therapeutic response to lovastatin (mevinolin) in nonfammilial hypercholesterolemia: a multicenter study. JAMA 1986;256:2829-2834.
21. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-682.
22. Stein E. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J Suppl 2001;3(Suppl E):E11-E16.
23. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia.AmJ Cardiol 1998;81:66B-69B.
24. Stein EA, Gipe D, Bergeron J, Gaudet D,Weiss R, Dufour R,WuR, Pordy R. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36.
25. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, Group SS. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR∗ Trial). Am J Cardiol 2003;92:152-160.
26. Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER; NCT01764633). http://www.clinicaltrials.gov/ct2/ show/NCT01764633?term=fourier&rank=1 (26 February 2013).
27. Ference BA, YooW, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, Williams KA Sr, Flack JM. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012;60: 2631-2639.